Physician profile
Yan Yang
NPI 1558532184
$1,391.40
in general payments reported to CMS, 2019-2025
26 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $63.84 · 2021: $274 · 2022: $219 · 2023: $208 · 2024: $143 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.36 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $296.28 | 2019-2024 | Farxiga |
| Davol INC. | $136.64 | 2021 | |
| Amgen INC. | $113.71 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Veloxis Pharmaceuticals, INC. | $110.48 | 2019-2025 | Envarsus |
| Bayer Healthcare Pharmaceuticals INC. | $91.39 | 2021-2023 | |
| Fresenius USA Marketing, INC. | $91.30 | 2019-2020 | |
| Horizon Therapeutics Plc | $70.61 | 2022-2023 | Krystexxa |
| Vifor Pharma, INC. | $43.56 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.56 | 2022-2023 | Livtencity |
| Astellas Pharma US INC | $39.11 | 2019 | |
| Merck Sharp & Dohme LLC | $37.87 | 2025 | Prevymis |
| Glaxosmithkline, LLC. | $29.97 | 2021 | |
| Eisai INC. | $26.38 | 2025 | |
| Ani Pharmaceuticals, INC. | $25.81 | 2022 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $24.41 | 2020 | |
| Calliditas Therapeutics US INC. | $22.32 | 2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $22.29 | 2022 | |
| Aurinia Pharma U.S., INC. | $22.13 | 2022 | |
| Ardelyx, INC. | $19.85 | 2023 | Ibsrela |
| Genzyme Corporation | $19.28 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.26 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.28 | 2023 | |
| Opko Pharmaceuticals, LLC | $16.73 | 2023 | Rayaldee |
| Renalytix Ai, INC. | $15.19 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $13.38 | 2024 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.